

# REQUEST FOR CONTINUED EXAMINATION (RCE) TRANSMITTAL

Address to :  
Commissioner for Patents  
Box RCE  
Washington, DC 20231

Application Number	09/418,887
Filing Date	October 15, 1999
First Named Inventor	Maurice Cohen
Art Unit	1642
Examiner Name	N. Davis
Attorney Docket Number	5967.US.D1

TECH CENTER 1600/2900  
JUN 21 2002

**This is a Request for Continued Examination (RCE) under 37 CFR 1.114 of the above-identified application.**  
Request for Continued Examination (RCE) practice under 37 CFR 1.114 does not apply to any utility or plant application filed prior to June 8, 1995, or to any design application. See Instruction Sheet for RCEs (not to be submitted to the USPTO) on page 2.

## 1. Submission required under 37 CFR 1.114

- a. ☒ Previously submitted
- i. ☒ Consider the amendment(s)/reply under 37 CFR 1.116 previously filed on February 28, 2002  
(Any unentered amendment(s) referred to above will be entered).
- ii. ☐ Consider the arguments in the Appeal Brief or Reply Brief previously filed on \_\_\_\_\_
- iii. ☒ Other See 1 in Addendum
- b. ☐ Enclosed
- i. ☐ Amendment/Reply
- ii. ☐ Affidavit(s)/Declaration(s)
- iii. ☐ Information Disclosure Statement (IDS)
- iv. ☒ Other Extension of Time Request;  
Return receipt postcard

## 2. Miscellaneous

- a. ☐ Suspension of action on the above-identified application is requested under 37 CFR 1.103(c) for a period of \_\_\_\_\_ months. (Period of suspension shall not exceed 3 months; Fee under 37 CFR 1.17(i) required)
- b. ☐ Other \_\_\_\_\_

## 3. Fees

The RCE fee under 37 CFR 1.17(e) is required by 37 CFR 1.114 when the RCE is filed.

- a. ☒ The Director is hereby authorized to charge the following fees, or credit any overpayments, to Deposit Account No. 01-0025
- i. ☒ RCE fee required under 37 CFR 1.17(e)
- ii. ☒ Extension of time fee (37 CFR 1.136 and 1.17)
- iii. ☐ Other \_\_\_\_\_
- b. ☐ Check in the amount of \$ \_\_\_\_\_ enclosed
- c. ☐ Payment by credit card (Form PTO-2038 enclosed)

**WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.**

COPY OF PAPERS  
ORIGINALLY FILED

## SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT REQUIRED

Name (Print/Type)	Lisa V. Mueller	Registration No. (Attorney/Agent)	38,978
Signature	<i>[Signature]</i>	Date	June 6, 2002

## CERTIFICATE OF MAILING OR TRANSMISSION

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner For Patents, Box RCE, Washington, DC 20231, or facsimile transmitted to the U.S. Patent and Trademark Office on the date shown below.

Name (Print/Type)	Wanda E. Smith	Date	June 7, 2002
Signature	<i>[Signature]</i>		



## Addendum


RECEIVED

JUN 21 2002

TECH CENTER 1600/2900

1. Terminal disclaimer, et al., Assoc. Power of Attorney; Declaration and Power of Attorney

COPY OF PAPERS  
ORIGINALLY FILED



RECEIVED

JUN 21 2002

TECH CENTER 1600/2900

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: M. Cohen, *et al.*

Serial No.: 09/418,887

Filed: October 15, 1999

For: REAGENTS AND METHODS USEFUL  
FOR DETECTING DISEASES OF THE  
PROSTATE

Examiner: N. Davis

Group Art Unit: 1642

Attorney Docket No.: 5967.US.D1

Date: February 25, 2002

Certificate of Mailing under 37 CFR §1.8(a):

I hereby certify that this paper (along with any  
paper referred to as being attached or enclosed) is  
being deposited with the United States Postal  
Service on the date shown below with sufficient  
postage as First Class Mail addressed to:

Assistant Commissioner for Patents  
Washington, D.C. 20231

on February 25, 2002

Name of person signing  
this certificate: Wanda E. Smith

Signature:

*Wanda E. Smith*

#140  
KD  
7-1602

AMENDMENT

Commissioner for Patents  
Washington, D.C. 20231

Sir:

In response to the Office Action mailed on October 19, 2001, please amend the  
above-referenced application as follows:

IN THE CLAIMS:

Please amend claims 21, 23, 27, 29, and 30 as follows:

21. (Amended). A test kit useful for detecting a target polynucleotide in a test  
sample, comprising:

a container containing at least one reagent polynucleotide having a sequence  
selected from the group consisting of SEQ ID NO:2, complete complements of SEQ ID  
NO:2, and degenerate coding sequences thereof.

COPY OF PAPERS  
ORIGINALLY FILED